BiotechTube

Paclitaxel plus PTK787

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasm Metastasis

Conditions

Neoplasm Metastasis, Carcinoma

Trial Timeline

May 1, 2005 → Aug 1, 2010

NCT ID
NCT00731861

About Paclitaxel plus PTK787

Paclitaxel plus PTK787 is a phase 1 stage product being developed by Novartis for Neoplasm Metastasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00731861. Target conditions include Neoplasm Metastasis, Carcinoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00731861Phase 1Completed

Competing Products

20 competing products in Neoplasm Metastasis

See all competitors
ProductCompanyStageHype Score
AB0024Gilead SciencesPhase 1
32
TTI-237PfizerPhase 1
32
852APfizerPhase 1
32
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
32
LY2780301Eli LillyPhase 1
33
PemetrexedEli LillyPhase 2
52
pemetrexed + cisplatinEli LillyPhase 1/2
41
IMC-3C5Eli LillyPhase 1
33
LY3295668Eli LillyPhase 1/2
41
Abemaciclib + ClarithromycinEli LillyPhase 1
33
Abemaciclib + FulvestrantEli LillyPhase 2
52
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
41
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
77
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + LeucovorinEli LillyPhase 1
33
LY2784544Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
enzastaurinEli LillyPhase 2
52
enzastaurin + gemcitabineEli LillyPhase 2
52
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
33

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85